Clinical Trials
13 trialsNCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05257057 2025-03-28
Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome
WellSpan Health
Completed
NCT05737797 2024-02-22
NIECE
Assistance Publique - Hôpitaux de Paris
Phase NA Unknown
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT04191226 2019-12-20
Genetic Mutation in Recurrent Cervical Cancer
Peking Union Medical College Hospital
Unknown
NCT04191252 2019-12-20
Genetic Mutation in Epithelial Ovarian Cancer
Peking Union Medical College Hospital
Unknown
NCT03744962 2018-11-19
MSI in Circulatory DNA of Endometrial Cancer
Peking Union Medical College Hospital
Unknown